ACOR - Acorda Therapeutics Stock Trading

Acorda Therapeutics ( ACOR ) is in a better position after addressing the convertible note overhang last year. In my previous article , I noted the company is uninvestable due to this substantial financing overhang as the company lacked the cash to pay the noteholders in 2021 and the conversi...

Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

Acorda Therapeutics, Inc. (ACOR) Q4 2019 Earnings Conference Call February 13, 2020 8:30 A.M. ET Company Participants Tierney Saccavino - Executive Vice President, Corporate Communications Ron Cohen - Chief Executive Officer Conference Call Participants Michael Yee - Jefferie...